WO2007017284A2 - Inhibitors of cancer cell, t-cell and keratinocyte proliferation - Google Patents

Inhibitors of cancer cell, t-cell and keratinocyte proliferation Download PDF

Info

Publication number
WO2007017284A2
WO2007017284A2 PCT/EP2006/007933 EP2006007933W WO2007017284A2 WO 2007017284 A2 WO2007017284 A2 WO 2007017284A2 EP 2006007933 W EP2006007933 W EP 2006007933W WO 2007017284 A2 WO2007017284 A2 WO 2007017284A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkenyl
alkynyl
alkyl
sarcoma
carcinoma
Prior art date
Application number
PCT/EP2006/007933
Other languages
English (en)
French (fr)
Other versions
WO2007017284A3 (en
Inventor
Johann Leban
Martin Kralik
Original Assignee
4Sc Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MX2008001900A priority Critical patent/MX2008001900A/es
Priority to EP06776753A priority patent/EP1922327A2/en
Priority to AU2006278150A priority patent/AU2006278150B2/en
Priority to CA002618750A priority patent/CA2618750A1/en
Priority to JP2008525489A priority patent/JP2009504596A/ja
Priority to BRPI0614902-2A priority patent/BRPI0614902A2/pt
Application filed by 4Sc Ag filed Critical 4Sc Ag
Priority to EA200800210A priority patent/EA014688B1/ru
Priority to NZ565793A priority patent/NZ565793A/en
Publication of WO2007017284A2 publication Critical patent/WO2007017284A2/en
Publication of WO2007017284A3 publication Critical patent/WO2007017284A3/en
Priority to IL189413A priority patent/IL189413A0/en
Priority to NO20080858A priority patent/NO20080858L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06156—Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
PCT/EP2006/007933 2005-08-10 2006-08-10 Inhibitors of cancer cell, t-cell and keratinocyte proliferation WO2007017284A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
EP06776753A EP1922327A2 (en) 2005-08-10 2006-08-10 Inhibitors of cancer cell, t-cell and keratinocyte proliferation
AU2006278150A AU2006278150B2 (en) 2005-08-10 2006-08-10 Inhibitors of cancer cell, T-cell and keratinocyte proliferation
CA002618750A CA2618750A1 (en) 2005-08-10 2006-08-10 Inhibitors of cancer cell, t-cell and keratinocyte proliferation
JP2008525489A JP2009504596A (ja) 2005-08-10 2006-08-10 癌細胞、ｔ細胞及びケラチノサイト増殖の阻害剤
BRPI0614902-2A BRPI0614902A2 (pt) 2005-08-10 2006-08-10 inibidores de proliferação de célula de cáncer, célula t e ceratinócito e uso dos referidos inibidores
MX2008001900A MX2008001900A (es) 2005-08-10 2006-08-10 Inhibidores de proliferacion de celulas cancerosas, celulas t y queratinocitos.
EA200800210A EA014688B1 (ru) 2005-08-10 2006-08-10 Ингибиторы пролиферации раковых клеток, т-клеток и кератиноцитов
NZ565793A NZ565793A (en) 2005-08-10 2006-08-10 Inhibitors of cancer cell, T-cell and keratinocyte proliferation
IL189413A IL189413A0 (en) 2005-08-10 2008-02-10 Inhibitors of cancer cell, t-cell and keratinocyte proliferation
NO20080858A NO20080858L (no) 2005-08-10 2008-02-18 Inhibitorer av kreftcelle-, T-celle- og keratinocytt-prolifirering

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05017391A EP1752467A1 (en) 2005-08-10 2005-08-10 Inhibitors of cancer cell, t-cell and keratinocyte proliferation
EP05017391.3 2005-08-10

Publications (2)

Publication Number Publication Date
WO2007017284A2 true WO2007017284A2 (en) 2007-02-15
WO2007017284A3 WO2007017284A3 (en) 2007-07-26

Family

ID=34981872

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/007933 WO2007017284A2 (en) 2005-08-10 2006-08-10 Inhibitors of cancer cell, t-cell and keratinocyte proliferation

Country Status (14)

Country Link
EP (4) EP1752467A1 (ja)
JP (1) JP2009504596A (ja)
KR (1) KR20080039895A (ja)
CN (2) CN101233146A (ja)
AU (1) AU2006278150B2 (ja)
BR (1) BRPI0614902A2 (ja)
CA (1) CA2618750A1 (ja)
EA (1) EA014688B1 (ja)
IL (1) IL189413A0 (ja)
MX (1) MX2008001900A (ja)
NO (1) NO20080858L (ja)
NZ (1) NZ565793A (ja)
WO (1) WO2007017284A2 (ja)
ZA (1) ZA200801359B (ja)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007097720A3 (en) * 2006-02-21 2007-11-08 Agency Science Tech & Res Method and reagents for treating hepatic fibrosis and inflammation
WO2011089167A1 (en) 2010-01-19 2011-07-28 Virologik Gmbh Kombination of proteasome inhibitors and anti -hepatitis medication for treating retroviral diseases
US8445678B2 (en) 2008-04-25 2013-05-21 Auburn University 2-quinoxalinol salen compounds and uses thereof
WO2018050656A2 (en) 2016-09-16 2018-03-22 Hsf Pharmaceuticals Inhibitors of heat shock factors and uses thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103588761B (zh) * 2013-10-22 2015-05-27 湖南大学 N-[1-(苯并呋喃-5-基)-2-氧代乙基]苯并吡喃-4-酰胺的制备与应用
JP6768270B2 (ja) * 2015-08-03 2020-10-14 学校法人神戸学院 ビオチン直接結合型タンパク質活性調節物質

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0543310A2 (en) * 1991-11-19 1993-05-26 Suntory Limited Dipeptide derivative and prophylactic and therapeutic agent for bone diseases containing the same
US5492895A (en) * 1992-02-14 1996-02-20 Corvas International, Inc. Inhibitors of thrombosis
WO2005016859A2 (en) * 2003-08-14 2005-02-24 Cephalon, Inc. Proteasome inhibitors and methods of using the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9300048D0 (en) * 1993-01-04 1993-03-03 Wellcome Found Endothelin converting enzyme inhibitors
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
ES2293651T3 (es) * 1995-11-28 2008-03-16 Cephalon, Inc. Inhibidores de cisteina y serina proteasas derivados de aminoacidos d.
WO2004014882A2 (en) 2002-08-09 2004-02-19 Axys Pharmaceuticals Proteasome inhibitors : peptide derivatives having c-terminal heteroaryl groups

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0543310A2 (en) * 1991-11-19 1993-05-26 Suntory Limited Dipeptide derivative and prophylactic and therapeutic agent for bone diseases containing the same
US5492895A (en) * 1992-02-14 1996-02-20 Corvas International, Inc. Inhibitors of thrombosis
WO2005016859A2 (en) * 2003-08-14 2005-02-24 Cephalon, Inc. Proteasome inhibitors and methods of using the same

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AUBIN SANDRINE ET AL: "Retro hydrazino-azapeptoids as peptidomimetics of proteasome inhibitors" JOURNAL OF MEDICINAL CHEMISTRY, vol. 48, no. 1, 13 January 2005 (2005-01-13), pages 330-334, XP002361264 ISSN: 0022-2623 *
BYCROFT B W ET AL: "Synthesis of a model relating to the chromophores of capreomycin and viomycin." TETRAHEDRON LETTERS, vol. 30, June 1969 (1969-06), pages 2539-2541, XP009075592 ISSN: 0040-4039 *
DODOU K ET AL: "Synthesis of gossypol atropisomers and derivatives and evaluation of their anti-proliferative and anti-oxidant activity" BIOORGANIC & MEDICINAL CHEMISTRY, vol. 13, no. 13, 1 July 2005 (2005-07-01), pages 4228-4237, XP004913668 ELSEVIER SCIENCE LTD, GB ISSN: 0968-0896 cited in the application *
HERAK, J. J. ET AL: "The action of hydrazines upon thiazolidine-4-carboxylic acids. I. Preparation of D-penicillamine from D-benzylpenilloic acid" CROATICA CHEMICA ACTA, vol. 49, no. 1, 1977, pages 141-148, XP009075733 CODEN: CCACAA; ISSN: 0011-1643 *
LINTON STEVEN D ET AL: "Acyl dipeptides as reversible caspase inhibitors. Part 2: Further optimization" BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 12, no. 20, 21 October 2002 (2002-10-21), pages 2973-2975, XP002361263 ISSN: 0960-894X *
MCCONNELL R M ET AL: "Synthesis and <13>C NMR equilibria studies of (1-<13>C)leupeptin and analogs" JOURNAL OF ORGANIC CHEMISTRY, vol. 63, no. 16, 1998, pages 5648-5655, XP009075600 UNITED STATES ISSN: 0022-3263 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007097720A3 (en) * 2006-02-21 2007-11-08 Agency Science Tech & Res Method and reagents for treating hepatic fibrosis and inflammation
GB2449601A (en) * 2006-02-21 2008-11-26 Agency Science Tech & Res Method and reagents for treating hepatic fibrosis and inflammation
GB2449601B (en) * 2006-02-21 2010-06-23 Agency Science Tech & Res Method and reagents for treating hepatic fibrosis and inflammation
US8445678B2 (en) 2008-04-25 2013-05-21 Auburn University 2-quinoxalinol salen compounds and uses thereof
WO2011089167A1 (en) 2010-01-19 2011-07-28 Virologik Gmbh Kombination of proteasome inhibitors and anti -hepatitis medication for treating retroviral diseases
WO2011089166A1 (en) 2010-01-19 2011-07-28 Virologik Gmbh Semicarbazone proteasome inhibitors for treating hiv and hepatitis infection
WO2018050656A2 (en) 2016-09-16 2018-03-22 Hsf Pharmaceuticals Inhibitors of heat shock factors and uses thereof

Also Published As

Publication number Publication date
AU2006278150B2 (en) 2012-03-08
WO2007017284A3 (en) 2007-07-26
EP1922327A2 (en) 2008-05-21
EA200800210A1 (ru) 2008-08-29
ZA200801359B (en) 2009-02-25
EP2284179A3 (en) 2011-08-31
EP1752467A1 (en) 2007-02-14
EP2284178A3 (en) 2011-09-14
EP2284179A2 (en) 2011-02-16
CN101233146A (zh) 2008-07-30
NZ565793A (en) 2011-06-30
EA014688B1 (ru) 2010-12-30
MX2008001900A (es) 2008-03-26
CN102174074A (zh) 2011-09-07
CA2618750A1 (en) 2007-02-15
JP2009504596A (ja) 2009-02-05
AU2006278150A1 (en) 2007-02-15
NO20080858L (no) 2008-04-10
EP2284178A2 (en) 2011-02-16
KR20080039895A (ko) 2008-05-07
IL189413A0 (en) 2008-06-05
BRPI0614902A2 (pt) 2011-04-19

Similar Documents

Publication Publication Date Title
US8106048B2 (en) Heterocyclic NF-κB inhibitors
US7812041B2 (en) Heterocyclic NF-κB inhibitors
US20100004258A1 (en) Novel Heterocyclic NF-kB Inhibitors
AU2006278150B2 (en) Inhibitors of cancer cell, T-cell and keratinocyte proliferation
WO2007104558A1 (en) Thiazoles as nf-kb inhibitors (proteasome inhibitors)
WO1995029892A1 (en) Hydroxamic acid and amino acid derivatives and their use as anti-arthritic agents
WO2007104557A2 (en) Novel heterocyclic nf-kb inhibitors
US20110263486A1 (en) Inhibitors of Cancer Cell, T-Cell and Keratinocyte Proliferation
US20100216772A1 (en) Novel Phenantridine Analogues and Uses Thereof
US7276606B2 (en) Phenantridine analogues and uses thereof

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 200680027869.9

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 200800210

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 1020087003111

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2006278150

Country of ref document: AU

Ref document number: 2008525489

Country of ref document: JP

Ref document number: MX/a/2008/001900

Country of ref document: MX

Ref document number: 1139/DELNP/2008

Country of ref document: IN

Ref document number: 565793

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 189413

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2618750

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006776753

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006278150

Country of ref document: AU

Date of ref document: 20060810

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006278150

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: A200802963

Country of ref document: UA

WWP Wipo information: published in national office

Ref document number: 2006776753

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0614902

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080211